Trial Profile

A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bicalutamide (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Adverse reactions; First in man
Acronyms Biolen-PC
Sponsors Alessa Therapeutics

Most Recent Events

06 May 2024 Results assessing Safety, Pk and Preliminary Efficacy Study of Localized Therapy Using Biolen (Bicalutamide) Implants for Early-Stage Prostate Cancer presented at the 119th Annual Meeting of the American Urological Association
23 Aug 2023 Status changed from recruiting to completed.
13 Jan 2021 Planned End Date changed from 30 Dec 2020 to 30 Dec 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com